Headlines about OncoSec Medical (NASDAQ:ONCS) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoSec Medical earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.7967866759608 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have effected Accern’s rankings:

A number of equities analysts have issued reports on ONCS shares. Maxim Group set a $5.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Monday, April 16th. HC Wainwright cut their target price on shares of OncoSec Medical from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, April 23rd. ValuEngine upgraded shares of OncoSec Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Dawson James restated a “buy” rating on shares of OncoSec Medical in a research report on Monday, July 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $4.33.

Shares of NASDAQ:ONCS traded down $0.07 during trading on Monday, reaching $1.44. The stock had a trading volume of 15,023 shares, compared to its average volume of 575,977. The firm has a market cap of $79.04 million, a PE ratio of -1.36 and a beta of 2.75. OncoSec Medical has a fifty-two week low of $0.88 and a fifty-two week high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Wednesday, June 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04). equities analysts expect that OncoSec Medical will post -0.81 earnings per share for the current year.

In other news, CFO Richard B. Slansky sold 84,984 shares of the business’s stock in a transaction that occurred on Thursday, July 5th. The shares were sold at an average price of $1.39, for a total value of $118,127.76. Following the completion of the transaction, the chief financial officer now owns 255,000 shares of the company’s stock, valued at $354,450. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Avtar S. Dhillon sold 37,575 shares of the business’s stock in a transaction that occurred on Thursday, July 5th. The shares were sold at an average price of $1.39, for a total transaction of $52,229.25. Following the completion of the transaction, the director now directly owns 181,002 shares of the company’s stock, valued at approximately $251,592.78. The disclosure for this sale can be found here. In the last three months, insiders sold 300,106 shares of company stock valued at $419,658. Company insiders own 5.50% of the company’s stock.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Read More: Short Selling

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.